P J Barter

Summary

Affiliation: The Heart Research Institute
Country: Australia

Publications

  1. ncbi request reprint Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel
    P J Barter
    Heart Research Institute, Camperdown, Sydney, NSW, Australia
    J Intern Med 259:247-58. 2006
  2. pmc Relationship between atorvastatin dose and the harm caused by torcetrapib
    Philip J Barter
    The Heart Research Institute, Sydney, Australia
    J Lipid Res 53:2436-42. 2012
  3. pmc The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit
    Belinda A Di Bartolo
    Lipid Research Group, Heart Research Institute, 7 Eliza St, Newtown, NSW 2042, Australia
    Lipids Health Dis 10:224. 2011
  4. doi request reprint Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Philip Barter
    The Heart Research Institute, 7 Eliza Street, Newtown, Sydney 2042, Australia
    Trends Pharmacol Sci 32:694-9. 2011
  5. ncbi request reprint The rationale for using apoA-I as a clinical marker of cardiovascular risk
    P J Barter
    The Heart Research Institute, Sydney, Australia
    J Intern Med 259:447-54. 2006
  6. ncbi request reprint Are we lowering LDL cholesterol sufficiently?
    Philip Barter
    The Heart Research Institute, Sydney, NSW, Australia
    Nat Clin Pract Cardiovasc Med 3:290-1. 2006
  7. ncbi request reprint Relationship between the concentration and antiatherogenic activity of high-density lipoproteins
    Philip J Barter
    The Heart Research Institute, Sydney, Australia
    Curr Opin Lipidol 17:399-403. 2006
  8. ncbi request reprint Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins
    Philip J Barter
    The Heart Research Institute and the Department of Medicine, University of Sydney, Australia
    Circulation 114:1315-20; discussion 1320. 2006
  9. ncbi request reprint Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia
    Philip Barter
    The Heart Research Institute, Camperdown, New South Wales, Australia
    J Clin Endocrinol Metab 92:2041-5. 2007
  10. ncbi request reprint Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
    Philip J Barter
    The Heart Research Institute, Sydney, Australia 2050
    Arterioscler Thromb Vasc Biol 28:39-46. 2008

Detail Information

Publications58

  1. ncbi request reprint Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel
    P J Barter
    Heart Research Institute, Camperdown, Sydney, NSW, Australia
    J Intern Med 259:247-58. 2006
    ..The evidence also indicates that the apo B/apo A-I ratio is superior to any of the conventional cholesterol ratios in patients without symptomatic vascular disease or diabetes to evaluate the lipoprotein-related risk of vascular disease...
  2. pmc Relationship between atorvastatin dose and the harm caused by torcetrapib
    Philip J Barter
    The Heart Research Institute, Sydney, Australia
    J Lipid Res 53:2436-42. 2012
    ..The harm could not be explained by torcetrapib-induced changes in lipid levels, blood pressure, or electrolytes. It is conceivable that higher doses of atorvastatin protected against the harm caused by torcetrapib...
  3. pmc The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit
    Belinda A Di Bartolo
    Lipid Research Group, Heart Research Institute, 7 Eliza St, Newtown, NSW 2042, Australia
    Lipids Health Dis 10:224. 2011
    ....
  4. doi request reprint Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Philip Barter
    The Heart Research Institute, 7 Eliza Street, Newtown, Sydney 2042, Australia
    Trends Pharmacol Sci 32:694-9. 2011
    ..Clinical outcome trials with dalcetrapib and anacetrapib are currently under way...
  5. ncbi request reprint The rationale for using apoA-I as a clinical marker of cardiovascular risk
    P J Barter
    The Heart Research Institute, Sydney, Australia
    J Intern Med 259:447-54. 2006
    ..The fact that the main apolipoprotein of HDLs, apoA-I, plays a prominent role in each of these functions adds support to the view that apoA-I should be measured as a component of the assessment of cardiovascular risk in humans...
  6. ncbi request reprint Are we lowering LDL cholesterol sufficiently?
    Philip Barter
    The Heart Research Institute, Sydney, NSW, Australia
    Nat Clin Pract Cardiovasc Med 3:290-1. 2006
  7. ncbi request reprint Relationship between the concentration and antiatherogenic activity of high-density lipoproteins
    Philip J Barter
    The Heart Research Institute, Sydney, Australia
    Curr Opin Lipidol 17:399-403. 2006
    ..The relationship between the concentration of high-density lipoprotein cholesterol and their protective function is addressed...
  8. ncbi request reprint Is it appropriate to make statins available over the counter? The argument against the appropriateness of over-the-counter statins
    Philip J Barter
    The Heart Research Institute and the Department of Medicine, University of Sydney, Australia
    Circulation 114:1315-20; discussion 1320. 2006
  9. ncbi request reprint Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia
    Philip Barter
    The Heart Research Institute, Camperdown, New South Wales, Australia
    J Clin Endocrinol Metab 92:2041-5. 2007
    ..The worldwide epidemic of overweight and obesity is setting the scene for a new wave of premature cardiovascular disease...
  10. ncbi request reprint Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?
    Philip J Barter
    The Heart Research Institute, Sydney, Australia 2050
    Arterioscler Thromb Vasc Biol 28:39-46. 2008
    ..It remains to be determined whether the combination of a fibrate plus statin reduces the risk beyond that achieved with a statin alone...
  11. ncbi request reprint HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
    Philip Barter
    Heart Research Institute, Sydney, Australia
    N Engl J Med 357:1301-10. 2007
    ..High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol...
  12. ncbi request reprint Effects of torcetrapib in patients at high risk for coronary events
    Philip J Barter
    Heart Research Institute, Camperdown, Sydney, NSW, Australia
    N Engl J Med 357:2109-22. 2007
    ..We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib...
  13. ncbi request reprint New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease
    Philip J Barter
    The Heart Research Institute, 114 Pyrmont Bridge Road, Camperdown, Sydney 2050, Australia
    Curr Cardiol Rep 9:493-8. 2007
    ..These results have potentially important clinical implications in regard to managing the acute vascular inflammation states that accompany acute coronary syndrome and acute ischemic stroke...
  14. pmc Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database
    Philip J Barter
    Heart Research Institute, Sydney, Australia
    J Lipid Res 51:1546-53. 2010
    ..The HDL-C increase achieved by all three statins was independent of LDL-C decrease. However, baseline HDL-C and TGs and the presence of diabetes were predictors of statin-induced increases in HDL-C...
  15. doi request reprint Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial
    Philip J Barter
    The Heart Research Institute, Sydney, Australia
    Circulation 124:555-62. 2011
    ..We now investigate effects on glucose homeostasis of inhibiting cholesteryl ester transfer protein with torcetrapib...
  16. doi request reprint HDL-C: role as a risk modifier
    Philip Barter
    The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW 2050, Australia
    Atheroscler Suppl 12:267-70. 2011
    ..Thus, there is a compelling case for targeting both the LDL and HDL fractions to reduce CV risk in people with dyslipidemia, high CV risk and low levels of HDL-C...
  17. ncbi request reprint Raising HDL-C can be achieved by both lifestyle changes and pharmacological means. Introduction
    Philip Barter
    The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW 2050, Australia
    Atheroscler Suppl 12:265-6. 2011
    ..This supplement will discuss the contribution of HDL-C as a possible predictor and modifiable risk factor for CV disease and will examine the potential role for pitavastatin in reducing residual CV risk...
  18. ncbi request reprint Aggressive management of obesity in children and young adults: the known challenges and potential opportunities
    P J Barter
    The Heart Research Institute, Sydney, Australia
    Clin Pharmacol Ther 81:627-30. 2007
    ..The world is confronted with an impending epidemic of premature cardiovascular disease (CVD) that is being fueled by an increase in the prevalence of central obesity...
  19. doi request reprint Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial
    Philip Barter
    The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, New South Wales, Australia 2042
    Am J Cardiol 104:10E-5E. 2009
    ..The potential of CETP inhibition to reduce cardiovascular risk will be determined by the outcome of ongoing clinical trials with CETP inhibitors that do not share the off-target effects of torcetrapib...
  20. doi request reprint Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I
    E Nobecourt
    Lipid Research Group, The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
    Diabetologia 51:1008-17. 2008
    ....
  21. ncbi request reprint The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase
    E Nobecourt
    Lipid Research Group, The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW, 2050, Australia
    Diabetologia 50:643-53. 2007
    ..The aim of this study was to determine how glycation affects the structure of apoA-I and its ability to activate lecithin:cholesterol acyltransferase (LCAT), a key enzyme in reverse cholesterol transport...
  22. ncbi request reprint The inflammation: lipoprotein cycle
    Philip Barter
    The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
    Atheroscler Suppl 6:15-20. 2005
    ..Additional protection from atherosclerosis may be provided by novel therapies that aim to increase plasma levels and activity of HDLs...
  23. ncbi request reprint Metabolic abnormalities: high-density lipoproteins
    Philip Barter
    The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney NSW 2050, Australia
    Endocrinol Metab Clin North Am 33:393-403. 2004
    ..The consequences of a low HDL concentration in this syndrome are addressed before the article concludes with a discussion of whether low HDL in the metabolic syndrome should be a therapeutic target...
  24. ncbi request reprint Managing diabetic dyslipidaemia--beyond LDL-C:HDL-C and triglycerides
    Philip Barter
    The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
    Atheroscler Suppl 7:17-21. 2006
    ....
  25. ncbi request reprint HDL: a recipe for longevity
    Philip Barter
    The Heart Research Institute, 145 Missenden Road, Camperdown, Sydney, NSW 2050, Australia
    Atheroscler Suppl 5:25-31. 2004
    ..As data accumulate on the protective role of HDLs, there is growing support for interventions that act to raise HDL-C concentrations...
  26. doi request reprint Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells
    K C Y McGrath
    Heart Research Institute, 114 Pyrmont Bridge Road, Camperdown, NSW, 2050, Australia
    Arterioscler Thromb Vasc Biol 29:877-82. 2009
    ..The purpose of this study was to investigate the ability of high-density lipoproteins (HDLs) to upregulate genes with the potential to protect against inflammation in endothelial cells...
  27. pmc Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia
    Philip Barter
    Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
    Am J Cardiol 102:1040-5. 2008
    ..In conclusion, several classes of drugs, including omega-3 fatty acids, can be used in combination with statins to achieve more global improvements in lipid profiles...
  28. ncbi request reprint Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids
    MyNgan Duong
    Department of Medicine, University of Adelaide, North Terrace, Australia
    Biochemistry 42:13778-85. 2003
    ..These results establish that EL and HL have different substrate specificities for rHDL phospholipids and that their interactions with the rHDL surface are regulated by phospholipids...
  29. ncbi request reprint High-density lipoproteins neutralize C-reactive protein proinflammatory activity
    Carol Wadham
    Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
    Circulation 109:2116-22. 2004
    ..CONCLUSIONS: The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components...
  30. ncbi request reprint Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein
    Nongnuch Settasatian
    Lipid Research Group, Heart Research Institute, Sydney, New South Wales 2050, Australia
    J Lipid Res 49:115-26. 2008
    ..It is concluded that apoE enhances the capacity of PLTP to remodel HDL but reduces the ability of HDL to participate in PLTP-mediated phospholipid transfers...
  31. ncbi request reprint Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells
    Philip J Barter
    Lipid Research Laboratory, Hanson Institute for Medical Research, Adelaide, Australia
    Curr Opin Lipidol 13:285-8. 2002
    ..The mechanism of this potentially anti-atherogenic effect of HDLs remains uncertain, as does its contribution to the cardioprotective effects of HDLs in vivo...
  32. ncbi request reprint Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study
    Herbert Schuster
    Humboldt University, Berlin, Germany
    Am Heart J 147:705-13. 2004
    ....
  33. ncbi request reprint Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling
    Kerry Anne Rye
    Lipid Research Laboratory, Hanson Institute, Adelaide, South Australia, Australia 5000
    Biochemistry 41:12538-45. 2002
    ..In conclusion, these results show that phospholipids play a key role in the CETP-mediated remodeling of rHDL and pre-beta apoA-I formation...
  34. ncbi request reprint Metabolism of apoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits
    Patrick Kee
    University Department of Medicine, Royal Adelaide Hospital, Adelaide, Australia
    Arterioscler Thromb Vasc Biol 22:1912-7. 2002
    ..This study investigates (1) the in vivo metabolism of apoA-I in each of these forms and (2) the effects of hepatic lipase (HL) on apoA-I metabolism...
  35. ncbi request reprint Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein A-I
    Kerry Anne Rye
    Heart Research Institute, Camperdown, Sydney, NSW, Australia
    Arterioscler Thromb Vasc Biol 24:421-8. 2004
    ..This review describes current knowledge regarding the formation, metabolism, and regulation of monomolecular, lipid-free/lipid-poor apoA-I in plasma...
  36. ncbi request reprint Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis
    Philip J Barter
    Hanson Institute and the Department of Cardiology, Royal Adelaide Hospital, Adelaide, Australia
    Arterioscler Thromb Vasc Biol 23:160-7. 2003
    ..Thus, it seems important and timely to test the hypothesis in randomized trials of humans that pharmacological inhibition of CETP retards the development of atherosclerosis...
  37. ncbi request reprint Apolipoprotein A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation
    Kerry Anne Rye
    Lipid Research Laboratory, Hanson Institute, Adelaide, South Australia 5000, Australia
    J Biol Chem 278:22530-6. 2003
    ....
  38. doi request reprint Antiinflammatory actions of HDL: a new insight
    Kerry Anne Rye
    Arterioscler Thromb Vasc Biol 28:1890-1. 2008
  39. doi request reprint Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment
    Gilles Lambert
    The Heart Research Institute, Sydney, Australia
    Clin Chem 54:1038-45. 2008
    ..Proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the LDL receptor (LDLr) in hepatocytes, and its expression in mouse liver has been shown to decrease with fenofibrate treatment...
  40. ncbi request reprint Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo
    Rajesh Puranik
    The Heart Research Institute, Lipid Research Group 145, Missenden Road, Sydney, NSW 2050, Australia
    Atherosclerosis 196:240-7. 2008
    ..These findings have potential implications for treating acute vascular inflammation in conditions such as acute coronary and stroke syndromes...
  41. ncbi request reprint Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E
    Kerry Anne Rye
    Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
    J Lipid Res 47:1025-36. 2006
    ....
  42. ncbi request reprint High-density lipoproteins as therapeutic targets
    Stephen J Nicholls
    The Heart Research Institute, Sydney, Australia
    Curr Opin Lipidol 16:345-9. 2005
    ..The best known antiatherogenic function of HDL particles relates to their ability to promote the efflux of cholesterol from cells. However, they also have antioxidant, antiinflammatory and antithrombotic properties...
  43. ncbi request reprint High-density lipoproteins enhance progenitor-mediated endothelium repair in mice
    Colin Tso
    Heart Research Institute, Sydney, NSW 2050, Australia
    Arterioscler Thromb Vasc Biol 26:1144-9. 2006
    ..Studies were conducted in C57BL/6J and in apolipoprotein E-deficient (apoE(-/-)) mice. We also investigated the possibility that high-density lipoproteins (HDL) may promote progenitor-mediated endothelial repair...
  44. ncbi request reprint Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism?
    Philip J Barter
    Circulation 113:1553-5. 2006
  45. ncbi request reprint Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits
    Stephen J Nicholls
    Heart Research Institute, Sydney, Australia
    Circulation 111:1543-50. 2005
    ..HDLs have antiinflammatory and antioxidant properties in vitro. This study investigates these properties in vivo...
  46. ncbi request reprint Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits
    Stephen J Nicholls
    The Heart Research Institute, Sydney, Australia
    Arterioscler Thromb Vasc Biol 25:2416-21. 2005
    ..Effects of HDL apolipoprotein and phospholipid composition have also been investigated...
  47. ncbi request reprint Antiinflammatory properties of HDL
    Philip J Barter
    The Heart Research Institute, 145 Missenden Rd, Camperdown, Sydney 2050, Australia
    Circ Res 95:764-72. 2004
    ..These antioxidant and antiinflammatory properties of HDL may be as important as its cholesterol efflux function in terms of protecting against the development of atherosclerosis...
  48. ncbi request reprint Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function
    Stephen J Nicholls
    The Heart Research Institute, Sydney, Australia
    J Am Coll Cardiol 48:715-20. 2006
    ..The purpose of this study was to investigate the influence of dietary fatty acids on the anti-inflammatory properties of high-density lipoproteins (HDL) and vascular function...
  49. ncbi request reprint Homocysteine and cardiovascular disease: is HDL the link?
    Philip J Barter
    Circ Res 99:565-6. 2006
  50. ncbi request reprint Apolipoprotein E enhances hepatic lipase-mediated hydrolysis of reconstituted high-density lipoprotein phospholipid and triacylglycerol in an isoform-dependent manner
    Neil J Hime
    Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales, Australia
    Biochemistry 43:12306-14. 2004
    ..These results show that apoE increases the rate of HL-mediated phospholipid and triacylglycerol hydrolysis in rHDL and that this influence is isoform dependent...
  51. ncbi request reprint Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
    John J P Kastelein
    Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    N Engl J Med 356:1620-30. 2007
    ..Torcetrapib, an inhibitor of cholesteryl ester transfer protein, may reduce atherosclerotic vascular disease by increasing levels of high-density lipoprotein (HDL) cholesterol...
  52. ncbi request reprint Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease
    Philip J Barter
    The Heart Research Institute, Camperdown, Sydney, Australia
    J Am Coll Cardiol 47:492-9. 2006
    ..Larger, long-term, randomized, clinical end point trials are required to determine whether the beneficial effects of CETP inhibitors on lipoprotein metabolism can translate into reductions in cardiovascular events...
  53. ncbi request reprint N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins
    Danielle Skropeta
    Lipid Research Group, Heart Research Institute, Camperdown, New South Wales 2050, Australia
    J Lipid Res 48:2047-57. 2007
    ..These data show that individual N-linked glycans have unique and important effects on the phospholipase activity and substrate specificity of EL...
  54. ncbi request reprint Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit
    Neil J Hime
    Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, New South Wales 2050, Australia
    J Lipid Res 47:115-22. 2006
    ..We conclude that, irrespective of the form in which apoA-II enters the plasma, it is rapidly incorporated into spherical HDLs that also contain apoA-I to form (A-I/A-II)HDL...
  55. ncbi request reprint Coronary plaque regression: role of low density lipoprotein-apheresis
    Philip J Barter
    J Am Coll Cardiol 40:228-30. 2002
  56. ncbi request reprint Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project)
    Diego F Wyszynski
    Department of Medicine Genetics Program, Boston University School of Medicine, Boston, MA, USA
    Am J Cardiol 95:194-8. 2005
    ..In subjects aged <35 years, atherogenic dyslipidemia frequently occurs in the absence of other metabolic syndrome risk factors...
  57. ncbi request reprint Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa
    Vivienne M Homer
    Canterbury Health Laboratories, 8001 Christchurch, New Zealand
    Atherosclerosis 196:659-66. 2008
    ..Our study therefore indicates that PCSK9 mediated inhibition of the LDLR does not require PCSK9 autocatalytic cleavage or secretion, suggesting that PCSK9 may also function intracellularly...
  58. ncbi request reprint Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia
    Yi Yu
    Department of Medicine Genetics Program, Boston University School of Medicine, Boston, MA, USA
    J Lipid Res 46:2202-13. 2005
    ..These data also indicate that a large proportion of the variance of TG levels in the Turkish population is explained by the interaction of multiple genetic loci...